Is Telomir Pharmaceuticals, Stock a Good Investment?
Telomir Pharmaceuticals, Investment Advice | TELO |
- Examine Telomir Pharmaceuticals,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Telomir Pharmaceuticals,'s leadership team and their track record. Good management can help Telomir Pharmaceuticals, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Telomir Pharmaceuticals,'s business and its evolving consumer preferences.
- Compare Telomir Pharmaceuticals,'s performance and market position to its competitors. Analyze how Telomir Pharmaceuticals, is positioned in terms of product offerings, innovation, and market share.
- Check if Telomir Pharmaceuticals, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Telomir Pharmaceuticals,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Telomir Pharmaceuticals, Common stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Telomir Pharmaceuticals, Common is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Telomir Pharmaceuticals, Stock
Researching Telomir Pharmaceuticals,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 34.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.56. Telomir Pharmaceuticals, had not issued any dividends in recent years.
To determine if Telomir Pharmaceuticals, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Telomir Pharmaceuticals,'s research are outlined below:
| Telomir Pharmaceuticals, generated a negative expected return over the last 90 days | |
| Telomir Pharmaceuticals, has high historical volatility and very poor performance | |
| Net Loss for the year was (16.53 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Telomir Pharmaceuticals, generates negative cash flow from operations | |
| Telomir Pharmaceuticals, has a poor financial position based on the latest SEC disclosures | |
| About 34.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells |
Telomir Pharmaceuticals, Quarterly Accounts Payable |
|
Earnings surprises can significantly impact Telomir Pharmaceuticals,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Telomir Pharmaceuticals,'s investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | -0.05 | -0.1 | -0.05 | 100 |
Telomir Pharmaceuticals, Analyst Ratings
Telomir Pharmaceuticals,'s analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Telomir Pharmaceuticals, stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Telomir Pharmaceuticals,'s financials, market performance, and future outlook by experienced professionals. Telomir Pharmaceuticals,'s historical ratings below, therefore, can serve as a valuable tool for investors.Telomir Pharmaceuticals,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 117.56 M.Market Cap |
|
Telomir Pharmaceuticals,'s profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (12.49) | (13.11) | |
| Return On Capital Employed | (1.32) | (1.25) | |
| Return On Assets | (12.49) | (13.11) | |
| Return On Equity | (25.71) | (24.42) |
Determining Telomir Pharmaceuticals,'s profitability involves analyzing its financial statements and using various financial metrics to determine if Telomir Pharmaceuticals, is a good buy. For example, gross profit margin measures Telomir Pharmaceuticals,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Telomir Pharmaceuticals,'s profitability and make more informed investment decisions.
Basic technical analysis of Telomir Stock
As of the 29th of March, Telomir Pharmaceuticals, has the Variance of 35.15, risk adjusted performance of 0.0069, and Coefficient Of Variation of (51,887). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Telomir Pharmaceuticals,, as well as the relationship between them.Telomir Pharmaceuticals,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Telomir Pharmaceuticals, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Telomir Pharmaceuticals,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Telomir Pharmaceuticals, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yanez Michelle over six months ago Acquisition by Yanez Michelle of 200000 shares of Telomir Pharmaceuticals, at 5.02 subject to Rule 16b-3 | ||
Bay Shore Trust over a year ago Purchase by Bay Shore Trust of 49000 shares of Telomir Pharmaceuticals | ||
Bay Shore Trust over a year ago Telomir Pharmaceuticals exotic insider transaction detected |
Understand Telomir Pharmaceuticals,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Telomir Pharmaceuticals,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0069 | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 4.72 | |||
| Coefficient Of Variation | (51,887) | |||
| Standard Deviation | 5.93 | |||
| Variance | 35.15 | |||
| Information Ratio | 0.0055 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | 0.3504 | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 28.29 | |||
| Value At Risk | (8.95) | |||
| Potential Upside | 9.49 | |||
| Skewness | 0.16 | |||
| Kurtosis | (0.25) |
| Risk Adjusted Performance | 0.0069 | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 4.72 | |||
| Coefficient Of Variation | (51,887) | |||
| Standard Deviation | 5.93 | |||
| Variance | 35.15 | |||
| Information Ratio | 0.0055 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | 0.3504 | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 28.29 | |||
| Value At Risk | (8.95) | |||
| Potential Upside | 9.49 | |||
| Skewness | 0.16 | |||
| Kurtosis | (0.25) |
Consider Telomir Pharmaceuticals,'s intraday indicators
Telomir Pharmaceuticals, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Telomir Pharmaceuticals, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Telomir Pharmaceuticals, Corporate Filings
8K | 19th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F5 | 4th of February 2025 The annual filing required by the Securities and Exchange Commission (SEC) from company insiders or beneficial owners | ViewVerify |
F4 | 25th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Telomir Stock media impact
Far too much social signal, news, headlines, and media speculation about Telomir Pharmaceuticals, that are available to investors today. That information is available publicly through Telomir media outlets and privately through word of mouth or via Telomir internal channels. However, regardless of the origin, that massive amount of Telomir data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Telomir Pharmaceuticals, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Telomir Pharmaceuticals, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Telomir Pharmaceuticals,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Telomir Pharmaceuticals, alpha.
Telomir Pharmaceuticals, Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Telomir Pharmaceuticals, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Telomir Pharmaceuticals, Corporate Executives
Elected by the shareholders, the Telomir Pharmaceuticals,'s board of directors comprises two types of representatives: Telomir Pharmaceuticals, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telomir. The board's role is to monitor Telomir Pharmaceuticals,'s management team and ensure that shareholders' interests are well served. Telomir Pharmaceuticals,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telomir Pharmaceuticals,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD ODonnell | Chief Cofounder | Profile | |
| Nathen CPA | Treasurer, CFO | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telomir Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Telomir Pharmaceuticals,'s value and its price, as these two are different measures arrived at by various means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.